The Bioactive Compounds of

2″-O-RhamnosylIcariside II Epimedium HIF-1α network pharmacology osteoporosis

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
29 May 2024
Historique:
received: 24 04 2024
revised: 23 05 2024
accepted: 27 05 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: epublish

Résumé

Osteoporosis is a global health challenge characterized by bone loss and microstructure deterioration, which urgently requires the development of safer and more effective treatments due to the significant adverse effects and limitations of existing drugs for long-term treatment. Traditional Chinese medicine, like

Identifiants

DOI: 10.3390/ph17060706 PMID: 38931373
pubmed: 38931373
pii: ph17060706
doi: 10.3390/ph17060706
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Shanghai Sailing Program
ID : 20YF1414300

Auteurs

Huizhong Dong (H)

School of Medicine, Shanghai University, Shanghai 200444, China.

Fen Tang (F)

School of Medicine, Shanghai University, Shanghai 200444, China.

Zilu Zhao (Z)

School of Medicine, Shanghai University, Shanghai 200444, China.

Wenxuan Huang (W)

School of Medicine, Shanghai University, Shanghai 200444, China.
ORCID: 0009-0009-5813-9471

Xiangyang Wan (X)

School of Medicine, Shanghai University, Shanghai 200444, China.

Zhanying Hong (Z)

School of Pharmacy, Naval Medical University, 325 Guohe Road, Shanghai 200433, China.

Ying Liu (Y)

Institute of Translational Medicine, Shanghai University, 99 Shangda Road, Shanghai 200444, China.

Xin Dong (X)

School of Medicine, Shanghai University, Shanghai 200444, China.

Si Chen (S)

School of Medicine, Shanghai University, Shanghai 200444, China.

Classifications MeSH